GSK PLC on Thursday said its subsidiary ViiV Healthcare has received marketing authorisation in China for its cabotegravir treatment, marketed as Vocabria.

The Brentford, London-based pharmaceutical company said China’s National Medical Products Administration has approved Vocabria to be used in combination with Johnson & Johnson subsidiary Janssen’s Rekambys to treat HIV.

ViiV Healthcare is a UK based firm focused on the research and development of HIV and AIDS therapies.

The firm noted that Rekambys, also known as rilpivirine was approved in China in July 2023.

It said Vocabria tablets have been approved for use with rilpivirine tablets as an oral option prior to injection, or as an oral therapy when patients will miss planned injections.

GSK said the approval is based on data from three trials, which showed the effectiveness and safety of the drug compared with stand oral care.

ViiV Chief executive Deborah Waterhouse said: ‘At ViiV Healthcare, we are proud to be able to offer innovative solutions that meet the evolving needs of people living with HIV. The approval of cabotegravir injection and rilpivirine long-acting injection marks a step forward in helping to change the treatment experience for some people living with HIV in China who may have challenges with daily HIV therapies.

‘We look forward to working closely with our partners in China to make this treatment available to those who could benefit from a long-acting regimen, part of our commitment to ensuring no person living with HIV is left behind.’

GSK shares were flat at 1,482.80 pence each on Thursday morning in London.

Copyright 2023 Alliance News Ltd. All Rights Reserved.